advanced nsclc
Showing 1 - 13 of 13
Lung Cancer, NSCLC Stage IV, Metastatic NSCLC - NSCLC Trial in Kansas City, Overland Park, Lee's Summit (Cabozantinib,
Not yet recruiting
- Lung Cancer
- +3 more
-
Kansas City, Kansas
- +3 more
May 12, 2023
Advanced NSCLC Trial in China (Gene Profile explore)
Recruiting
- Advanced NSCLC
- Gene Profile explore
-
Beijing, China
- +14 more
Jan 27, 2023
Advanced NSCLC, Metastatic Lung Cancer Trial in East Syracuse, Cleveland, Bellingham (Adagrasib in combination with
Recruiting
- Advanced NSCLC
- Metastatic Lung Cancer
- Adagrasib in combination with pembrolizumab
- Pembrolizumab
-
East Syracuse, New York
- +2 more
Nov 28, 2022
Advanced NSCLC Trial in Yangzhou (camrelizumab + famitinib, famitinib, docetaxel)
Recruiting
- Advanced NSCLC
- camrelizumab + famitinib
- +2 more
-
Yangzhou, Jiangsu, ChinaSubei People's Hospital of Jiangsu Province
Jan 11, 2022
Advanced NSCLC Trial in La Jolla (Nivolumab, Oxaliplatin, Ipilimumab)
Recruiting
- Advanced NSCLC
- Nivolumab
- +2 more
-
La Jolla, CaliforniaUC San Diego Moores Cancer Center
Apr 1, 2021
Circulating Tumor Cells Gene Mutation Detection From Advanced
Unknown status
- Advanced NSCLC
- +2 more
- nonintervention
- (no location specified)
Jan 10, 2020
Advanced NSCLC Trial in Beijing (Alflutinib)
Unknown status
- Advanced NSCLC
-
Beijing, Chinacancer hospital Chinese academy of medical sciences
Jan 2, 2020
Advanced Nsclc Trial in Jinan (Thalidomide, pemetrexed, cisplatin)
Unknown status
- Advanced Nsclc
- Thalidomide
- +3 more
-
Jinan, Shandong, ChinaQilu hospital of Shandong University
Jun 3, 2019
Advanced NSCLC, First Line Treatment Trial in Heidelberg (Exercise Intervention, Care-Management-Phone-Calls)
Completed
- Advanced NSCLC
- First Line Treatment
- Exercise Intervention
- Care-Management-Phone-Calls
-
Heidelberg, Baden-Württemberg, GermanyThoracic Oncology Clinic for Thoracic Diseases
Aug 22, 2018
Advanced Nsclc Trial in Chongqing (radiotherapy)
Unknown status
- Advanced Nsclc
- radiotherapy
-
Chongqing, ChinaXinqiao Hospital of Chongqing
Mar 7, 2017
Advanced NSCLC, Recurrent NSCLC Trial in Tianjin (Endostar(rh recombinant endostatin) plus Docetaxel, Placebo plus Docetaxel)
Unknown status
- Advanced NSCLC
- Recurrent NSCLC
- Endostar(rh recombinant endostatin) plus Docetaxel
- Placebo plus Docetaxel
-
Tianjin, ChinaCancer Hospital of Tianjin Medical University
Jan 22, 2010